Prospects for non-immunological molecular therapeutics in melanoma

Journal of B.U.ON.

Volumn 15, Issue 1, 2010, Pages 9-18

  Eustace, Alex J ^a   Mahgoub, T ^a,b   Tryfonopoulos, D ^a,b   O'Donovan, N ^a   Crown, J ^a,b  

^a DUBLIN CITY UNIVERSITY   (Ireland)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Angiogenesis; BRAF; HSP90; PARP; PI3K AKT; Tyrosine kinase

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 1 (2 METHOXYETHOXY) 2 METHYL 3 (2 PYRAZINYLMETHYL)NAPHTHO[2,3 D]IMIDAZOLE 4,9 DIONE; 2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE; 2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; AUY 922; AXITINIB; B RAF KINASE; BEVACIZUMAB; BIIB 021; BOSUTINIB; CARBOPLATIN; CEDIRANIB; CHIR 265; DACARBAZINE; DEFOROLIMUS; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; GPI 15427; HEAT SHOCK PROTEIN 90; IMATINIB; INO 1001; LY 2181308; MITOGEN ACTIVATED PROTEIN KINASE; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OLAPARIB; PACLITAXEL; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PLX 4032; PLX 4720; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RAPAMYCIN; RAS PROTEIN; RO 5126766; SNX 2112; SORAFENIB; SPC 3042; SUNITINIB; SURVIVIN; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 147; XL 765; XL 880; YM 115;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG TARGETING; GENE MUTATION; HUMAN; MELANOMA; METASTASIS; OVERALL SURVIVAL; PROGNOSIS; REVIEW; SYSTEMIC THERAPY; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; DRUGS, INVESTIGATIONAL; HUMANS; MELANOMA; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 77950971349     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (120)

1. Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol 2009; 27: 3-9.
2. Trinh VA. Current management of metastatic melanoma. Am J Health Syst Pharm 2008; 65 (24 Suppl 9): S3-8.
3. Mitchell MS. Chemotherapy for melanoma: the resultant of conflicting vectors. J Clin Oncol 2004; 22: 2043-2045.
4. Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 2007; 25: 5426-5434. (Pubitemid 350232219)
5. Fang L, Lonsdorf AS, Hwang ST. Immunotherapy for advanced melanoma. J Invest Dermatol 2008; 128: 2596-2605.
6. Rodolfo M, Daniotti, M, Vallacchi V. Genetic progression of metastatic melanoma. Cancer Lett 2004; 214: 133-147.
7. Kasper B, D'Hondt V, Vereecken P, Awada A. Novel treatment strategies for malignant melanoma: a new beginning? Crit Rev Oncol Hematol 2007; 62: 16-22.
8. Smalley KS, Herlyn, M. Loitering with intent: new evidence for the role of BRAF mutations in the proliferation of melanocytic lesions. J Invest Dermatol 2004; 123: xvi-xvii. (Pubitemid 39281597)
9. Houben R, Becker JC, Kappel A et al. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog 2004; 3: 6. (Pubitemid 38751386)
10. Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, Robertson GP. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 2005; 65: 2412-2421. (Pubitemid 40490153)
11. Murphy DA, Makonnen S, Lassoued W, Feldman, MD, Carter C, Lee WM. Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). Am J Pathol 2006; 169: 1875-1885.
12. Eisen T, Ahmad T, Flaherty KT et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 2006; 95: 581-586. (Pubitemid 44325897)
13. McDermott DF, Sosman, JA, Gonzalez R et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol 2008; 26: 2178-2185.
14. Agarwala SS, Keilholz U, Hogg D et al. Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma. J Clin Oncol 2007; 25(18S): 8510.
15. Tsai J, Lee JT, Wang W et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 2008; 105: 3041-3046. (Pubitemid 351723664)
16. Dhillon, AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007; 26: 3279-3290. (Pubitemid 46763021)
17. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003; 4: 257-262. (Pubitemid 37329790)
18. Curtin, JA, Stark MS, Pinkel D, Hayward NK, Bastian BC. PI3-kinase subunits are infrequent somatic targets in melanoma. J Invest Dermatol 2006; 126: 1660-1663. (Pubitemid 43910386)
19. Singh, RS, Diwan H, Zhang PS, Prieto VG. Phosphoinositide 3-kinase is not overexpressed in melanocytic lesions. J Cutan Pathol 2007; 34: 220-225.
20. Robertson GP. Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Metastasis Rev 2005; 24: 273-285.
21. Dai DL, Martinka, M, Li G. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J Clin Oncol 2005; 23: 1473-1482. (Pubitemid 46260035)
22. Stahl JM, Sharma A, Cheung M et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 2004; 64: 7002-7010. (Pubitemid 39331010)
23. Tsao H, Mihm MC, Jr, Sheehan C. PTEN expression in normal skin, acquired melanocytic nevi, and cutaneous melanoma. J Am Acad Dermatol 2003; 49: 865-872. (Pubitemid 37314875)
24. Goel VK, Lazar, AJ, Warneke CL, Redston MS, Haluska FG. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol 2006; 126: 154-160. (Pubitemid 43336107)
25. Karbowniczek M, Spittle CS, Morrison T, Wu H, Henske EP. mTOR is activated in the majority of malignant melanomas. J Invest Dermatol 2008; 128: 980-987. (Pubitemid 351374287)
26. Dancey JE. Molecular targeting: PI3 kinase pathway. Ann Oncol 2004; 15 (Suppl 4): iv233-239.
27. McCormick F. Cancer: survival pathways meet their end. Nature 2004; 428(6980): 267-269. (Pubitemid 38418785)
28. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 2008; 8: 393-412.
29. Wulff BC, Kusewitt, DF, VanBuskirk AM, Thornas-Ahner JM, Duncan FJ, Oberyszyn TM. Sirolimus reduces the incidence and progression of UVB-induced skin cancer in SKH mice even with co-administration of cyclosporine A. J Invest Dermatol 2008; 128: 2467-2473.
30. Bundscherer A, Hafner C, Maisch T, Becker B, Landthaler M, Vogt T. Antiproliferative and proapoptotic effects of rapamycin and celecoxib in malignant melanoma cell lines. Oncol Rep 2008; 19: 547-553. (Pubitemid 351176119)
31. Romano MF, Avellino R, Petrella A, Bisogni R, Romano S. Venuta S. Rapamycin inhibits doxorubicin-induced NF-kappaB/Rel nuclear activity and enhances the apoptosis of melanoma cells. Eur J Cancer 2004; 40: 2829-2836. (Pubitemid 39574738)
32. Molhoek KR, Brautigan DL, Slingluff CL Jr. Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin. J Transl Med 2005; 3: 39.
33. Thallinger C, Poeppl W, Pratscher B et al. CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotranplantation model. Pharmacology 2007; 79: 207-213. (Pubitemid 46848540)
34. Margolin K, Longmate J, Baratta T et al. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 2005; 104: 1045-1048. (Pubitemid 41170233)
35. Krasilnikov M, Adler V, Fuchs SY et al. Contribution of phosphatidylinositol 3-kinase to radiation resistance in human melanoma cells. Mol Carcinog 1999; 24: 64-69. (Pubitemid 29070245)
36. Bedogni B, O'Neill MS, Welford SM et al. Topical treatment with inhibitors of the phosphatidylinositol 3'-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice. Cancer Res 2004; 64: 2552-2560. (Pubitemid 38523912)
37. Baumann, P, Mandl-Weber S, Oduncu F, Schmidmaier R. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Exp Cell Res 2009; 315: 485-497.
38. Maira SM, Stauffer F, Brueggen J et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008; 7: 1851-1863.
39. Scotlandi K, Manara MC, Nicoletti G et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 2005; 65: 3868-3876. (Pubitemid 40616368)
40. Ernst DS, Eisenhauer E, Wainman N et al. Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest New Drugs 2005; 23: 569-575. (Pubitemid 43162477)
41. Lasithiotakis KG, Sinnberg TW, Schittek B et al. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J Invest Dermatol 2008; 128: 2013-2023. (Pubitemid 352001225)
42. Bedogni B, Welford SM, Kwan AC, Ranger-Moore J, Saboda K, Powell MB. Inhibition of phosphatidylinositol-3-kinase and mitogen-activated protein kinase kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPRas mouse model. Mol Cancer Ther 2006; 5: 3071-3077. (Pubitemid 46092048)
43. Meier F, Busch S, Lasithiotakis K et al. Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. Br J Dermatol 2007; 156: 1204-1213. (Pubitemid 47029801)
44. Ronnstrand L. Signal transduction via the stem cell factor receptor/c-Kit. Cell Mol Life Sci 2004; 61: 2535-2548. (Pubitemid 39586516)
45. Giehl A, Naegle U, Volkenandt M, Berking C. Protein expression of melanocyte growth factors (bFGF, SCF) and their receptors (FGFR-1, c-kit) in nevi and melanoma. J Cutan Pathol 2007; 34: 7-14.
46. Grichnik JM, Burch JA, Burchette J, Shea CR. The SCF/KIT pathway plays a critical role in the control of normal human melanocyte homeostasis. J Invest Dermatol 1998; 111: 233-238. (Pubitemid 28354709)
47. Marquette A, Bagot M, Bensussan A, Dumaz N. Recent discoveries in the genetics of melanoma and their therapeutic implications. Arch Immunol Ther Exp (Warsz) 2007; 55: 363-372.
48. Becker JC, Blocker EB, Schadendorf D, Ugurel S. Imatinib in melanoma: A selective treatment option based on KIT mutation status? J Clin Oncol 2007; 25: E9-E9.
49. Rivera RS, Nagatsuka H, Gunduz M et al. C-kit protein expression correlated with activating mutations in K7T gene in oral mucosal melanoma. Virchows Arch 2008; 452: 27-32.
50. Janku F, Novotny J, Julis I et al. KIT receptor is expressed in more than 50% of early-stage malignant melanoma: a retrospective study of 261 patients. Melanoma Res 2005; 15:251-256. (Pubitemid 41127460)
51. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24: 4340-4346. (Pubitemid 46630793)
52. Holden JA, Willmore-Payne C, Layfield LJ. Tyrosine kinase activating mutations in human malignancies: implications for diagnostic pathology. Exp Mol Pathol 2008; 85: 68-75.
53. Smalley KS, Contractor R, Nguyen TK et al. Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. Cancer Res 2008; 68: 5743-5752.
54. Uziel O, Fenig E, Nordenberg J et al. Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br J Cancer 2005; 92: 1881-1891.
55. Eton O, Billings L, Kim K et al. Phase II trial of imatinib mesylate (STI-571) in metastatic melanoma (7M). J Clin Oncol 2004; 22: 717S-717S.
56. Barnekow A, Paul E, Schartl M. Expression of the c-src protooncogene in human skin tumors. Cancer Res 1987; 47: 235-240. (Pubitemid 17002129)
57. Marchetti D, Parikh N, Sudol M, Gallick GE. Stimulation of the protein tyrosine kinase c-Yes but not c-Src by neurotrophins in human brain-metastatic melanoma cells. Oncogene 1998; 16: 3253-3260. (Pubitemid 28330423)
58. Huang J, Asawa T, Takato T, Sakai R. Cooperative roles of Fyn and cortactin in cell migration of metastatic murine melanoma. J Biol Chem 2003; 278: 48367-48376. (Pubitemid 37523292)
59. Qi J, Wang J, Romanyuk O, Siu CH. Involvement of Src family kinases in N-cadherin phosphorylation and beta-catenin dissociation during transendothelial migration of melanoma cells. Mol Biol Cell 2006; 17: 1261-1272. (Pubitemid 43376547)
60. Wellbrock C, Weisser C, Geissinger E, Tropprnair J, Schartl M. Activation of p59(Fyn) leads to melanocyte dedifferentiation by influencing MKP-1-regulated mitogen-activated protein kinase signaling. J Biol Chem 2002; 277: 6443-6454. (Pubitemid 34968440)
61. Loganzo F Jr, Dosik JS, Zhao Y et al. Elevated expression of protein tyrosine kinase c-Yes, but not c-Src, in human malignant melanoma. Oncogene 1993; 8: 2637-2644. (Pubitemid 23279091)
62. Homsi J, Cubitt C, Daud A. The Src signaling pathway: a potential target in melanoma and other malignancies. Expert Opin Ther Targets 2007; 11: 91-100. (Pubitemid 46099755)
63. Deconti R, Messina J, Decker M et al. Expression of STAT proteins and interferon-α receptors in benign and malignant melanocytic lesions: correlation with recurrence. ASCO Ann Meet Proc 2004; 22(14S): 7514 (abstr).
64. Niu G, Bowman T, Huang M et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 2002; 21: 7001-7010. (Pubitemid 35252974)
65. Lombardo LJ, Lee FY, Chen P et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47: 6658-6661. (Pubitemid 40053752)
66. Eustace AJ, Crown J, Clynes M, O'Donovan N. Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines. J Transl Med 2008; 6: 53.
67. Nam S, Kim D, Cheng JQ et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005; 65: 9185-9189. (Pubitemid 41507982)
68. Finn RS, Dering J, Ginther C et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007; 105: 319-326.
69. Serrels A, Macpherson IR, Evans TR et al. Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol Cancer Ther 2006; 5: 3014-3022. (Pubitemid 46092042)
70. Hennequin LF, Allen J, Breed J et al. N-(5-chloro-1,3-benzodioxol-4-yl)- 7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy) quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J Med Chem 2006; 49: 6465-6488.
71. Jallal H, Valentino ML, Chen G, Boschelli F, Ali S, Rabbani SA. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res 2007; 67: 1580-1588. (Pubitemid 46383382)
72. Furge KA, Zhang YW, Vande Woude GF. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene 2000; 19: 5582-5589.
73. Peruzzi B, Bottaro DP. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 2006; 12: 3657-3660. (Pubitemid 44000247)
74. Natali PG, Nicotra MR, Di Renzo MF et al. Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression. Br J Cancer 1993; 68: 746-750.
75. Slominski A, Wortsman J, Carlson AJ, Matsuoka LY, Balch CM, Mihm MC. Malignant melanoma. Arch Pathol Lab Med 2001; 125: 1295-1306.
76. Barnhill RL, Mihm MC Jr. The histopathology of cutaneous malignant melanoma. Semin Diagn Pathol 1993; 10: 47-75.
77. Cruz J, Reis-Filho JS, Silva P, Lopes JM. Expression of c-met tyrosine kinase receptor is biologically and prognostically relevant for primary cutaneous malignant melanomas. Oncology 2003; 65: 72-82. (Pubitemid 36829093)
78. Hsu MY, Meier F, Herlyn M. Melanoma development and progression: a conspiracy between tumor and host. Differentiation 2002; 70: 522-536. (Pubitemid 36194317)
79. Li G, Schaider H, Satyamoorthy K, Hanakawa Y, Hashimoto K, Herlyn M. Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. Oncogene 2001; 20: 8125-8135. (Pubitemid 34028337)
80. Jhappan C, Noonan FP, Merlino G. Ultraviolet radiation and cutaneous malignant melanoma. Oncogene 2003; 22: 3099-3112. (Pubitemid 36713762)
81. Puri N, Ahmed S, Janamanchi V et al. c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res 2007; 13: 2246-2253. (Pubitemid 46649894)
82. Streit M, Detmar M. Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene 2003; 22: 3172-3179.
83. Kim S, Yazici YD, Calzada G et al. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther 2007; 6: 1785-1792. (Pubitemid 46954055)
84. Liu L, Cao Y, Chen C et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006; 66: 11851-11858.
85. Perez DG, Suman VJ, Fitch TR et al. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. Cancer 2009; 115: 119-127.
86. Wedge SR, Kendrew J, Hennequin LF et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005; 65: 4389-4400. (Pubitemid 40775678)
87. Takeda M, Arao T, Yokote H et al. AZD2171 shows potent anti-tumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor. Clin Cancer Res 2007; 13: 3051-3057. (Pubitemid 46849582)
88. Fruehauf JP, Lutzky J, McDermott DF et al. Axitinib (AG-013736) in patients with metastatic melanoma: A phase II study. J Clin Oncol 2008; 26 (Suppl): 9006 (abstr).
89. Virag L, Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 2002; 54: 375-429.
90. Tentori L, Leonetti C, Scarsella M et al. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma. FASEB J 2006; 20: 1709-1711. (Pubitemid 44943780)
91. Tentori L, Graziani G. Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res 2005; 52: 25-33. (Pubitemid 40725597)
92. Plummer ER. Inhibition of poly(ADP-ribose) polymerase in cancer. Curr Opin Pharmacol 2006; 6: 364-368.
93. Staibano S, Pepe S, Lo Muzio L et al. Poly(adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region. Hum Pathol 2005; 36: 724-731. (Pubitemid 41112026)
94. Tentori L, Leonetti C, Scarsella M et al. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res 2003; 9: 5370-5379. (Pubitemid 37413592)
95. Palma JP, Rodriguez LE, Bontcheva-Diaz VD et al. The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo. Anticancer Res 2008; 28: 2625-2635.
96. Yang SK, Rubinstein L, Gutierrez M et al. NCI Phase 0 Working Group, Phase 0 pharmacodynamic study of poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with refractory solid tumors and lymphomas: Immunohistochemistry results. J Clin Oncol 2008; 26: 3580 (abstr).
97. Wang C, Kim AB K, Papadopoulos N, Hwu W, Hwu P. Evaluation of Tolerability, Safety, and Pharmacokinetics of INO-1001 Plus Temozolomide (TMZ) in patients with Unresectable Stage III/IV Melanoma. J Clin Oncol 2006; 24(18S): 12015 (abstr).
98. Plummer R, Lorigan P, Evans J et al. First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AGO14699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). J Clin Oncol 2006; 24: 24(18S): 8013 (abstr).
99. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol 1999; 17: 2941-2953.
100. Thomas WD, Hersey P. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J Immunol 1998; 161: 2195-2200. (Pubitemid 28397029)
101. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003; 22: 8581-8589.
102. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000; 6: 127-134. (Pubitemid 30064984)
103. Gradilone A, Gazzaniga P, Ribuffo D etal. Survivin, bcl-2,bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients. J Clin Oncol 2003; 21: 306-312. (Pubitemid 46606160)
104. Takeuchi H, Morton DL, Elashoff D, Hoon DS. Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine. Int J Cancer 2005; 117: 1032-1038. (Pubitemid 41688581)
105. Grossman D, McNiff JM, Li F, Altieri DC. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 1999; 113: 1076-1081. (Pubitemid 30013356)
106. Ding Y, Prieto VG, Zhang PS et al. Nuclear expression of the antiapoptotic protein survivin in malignant melanoma. Cancer 2006; 106: 1123-1129. (Pubitemid 43297352)
107. Brennan DJ, Rexhepaj E, O'Brien SL et al. Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer. Clin Cancer Res 2008; 14: 2681-2689.
108. Shirai K, Suzuki Y, Oka K et al. Nuclear survivin expression predicts poorer prognosis in glioblastoma. J Neurooncol 2009; 91: 353-358.
109. Nakahara T, Takeuchi M, Kinoyama I et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007; 67: 8014-8021. (Pubitemid 47395135)
110. Gonzalez RKL, Samlowski W, Cranmer L et al. A phase II study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2007; 25: (18S): 8538 (abstr).
111. Hansen JB, Fisker N, Westergaard M et al. SPC3042: a proapoptotic survivin inhibitor. Mol Cancer Ther 2008; 7: 2736-2745.
112. Taldone T, Gozman A, Maharaj R, Chiosis G. Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol 2008; 8: 370-374.
113. Banerji U. Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res 2009; 15: 9-14.
114. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 2002; 8 (4 Suppl): S55-S61. (Pubitemid 34297080)
115. Grbovic OM, Basso AD, Sawai A etal. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci U S A 2006; 103: 57-62.
116. Gray-Schopfer VC, da Rocha Dias S, Marais R. The role of BRAF in melanoma. Cancer Metastasis Rev 2005; 24: 165-183.
117. McCarthy MM, Pick E, Kluger Y et al. HSP90 as a marker of progression in melanoma. Ann Oncol 2008; 19: 590-594.
118. Banerji U, Walton M, Raynaud F et al. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin Cancer Res 2005; 11 (19Pt 1): 7023-7032. (Pubitemid 41428762)
119. Banerji U, Affolter A, Judson I, Marais R, Workman P. BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors. Mol Cancer Ther 2008; 7: 737-739. (Pubitemid 351551026)
120. Soht DB, Osman I, Polsky D et al. Phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res 2008; 14: 8302-8307.